The transcriptome of GTML GEMM tumors aligned with group 3 medulloblastoma, a subgroup in which patient tumors commonly amplify CMYC and only rarely amplify MYCN (Northcott et al., 2017). This evidence concerns the gene MYCN and medulloblastoma.